Study Group 2 (n = 27) Control Group 2 (n=13) p-value
Chemotherapy regimens of fourth-line
treatment
Carboplatin based 14 (51.9%) 4 (30.8%)
Nedaplatin based 6 (22.2%) 4 (30.8%)
Cisplatin based 2 (7.4%) 0 (0.0%)
Oxaliplatin based 1 (3.7%) 0 (0.0%)
Lobaplatin based 1 (3.7%) 3 (23.1%)
Multiple platinum 3a (11.1%) 2b (15.4%)